Fangchinoline targets human renal cell carcinoma cells through modulation of apoptotic and non‑apoptotic cell deaths
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Young Yun Jung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, the Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Benzylisoquinolines, Apoptosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
The process of apoptosis is one of the essential processes involved in maintenance of homeostasis in the human body. It can aid to remove misfolded proteins or cellular organelles. This sequence is especially necessary in cancer cells. However, specifically targeting already apoptotic pathways can induce drug resistance in cancer cells and hence drugs can induce cell death by alternative mechanism. We investigated whether fangchinoline (FCN) can target renal carcinoma cells by inducing multiple cell death mechanisms. Both paraptosis, autophagy, and apoptosis were induced by FCN through stimulation of diverse molecular signaling pathways. FCN induced ROS production with GSH/GSSG imbalance, and ER stress. In addition, formation of autophagosome and autophagy related markers were stimulated by FCN. Moreover, FCN induced cell cycle arrest and PARP cleavage. Except for blocking protein synthesis, these three cell death pathways were found to be complementarily working together with each other. FCN also exhibited synergistic effects with paclitaxel in inducing programmed cell death in RCC cells. Our data indicates that FCN could induce apoptotic cell death and non-apoptotic cell death pathways and can be con-tribute to development of novel cancer prevention or therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, the Republic of Korea.
- College of Korean Medicine, Dongguk University, 32 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, the Republic of Korea.
- Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, the Republic of Korea. Electronic address: ksahn@khu.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Jung, Y. Y., Baek, S. H., Um, J. Y., & Ahn, K. S. (2024). Fangchinoline targets human renal cell carcinoma cells through modulation of apoptotic and non‑apoptotic cell deaths. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155445
Vancouver
Jung YY, Baek SH, Um JY, Ahn KS. Fangchinoline targets human renal cell carcinoma cells through modulation of apoptotic and non‑apoptotic cell deaths. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155445
BibTeX
@article{Jung2024,
author = {Jung, Young Yun and Baek, Seung Ho and Um, Jae-Young and Ahn, Kwang Seok},
title = {Fangchinoline targets human renal cell carcinoma cells through modulation of apoptotic and non‑apoptotic cell deaths},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155445}
}
EUVIMED